Clinical Trial Update: Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating temsirolimus combined with neratinib in metastatic HER2-amplified or triple-negative breast cancer; results posted after completion o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Temsirolimus (temsirolimus)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-11-07